Clinical Trial Updates (SCD)
Ferriprox® (deferiprone)
Update: 25 April 2022
No update available
Update: 10 January 2022
No update available.
Update: 27 October 2021
- Regulators in Brazil have approved Ferriprox (deferiprone) for people with sickle cell disease (SCD) or other anemias. The decision by Brazil’s National Health Surveillance Agency follows a similar label expansion in the U.S. — where the therapy was available for thalassemia patients when current iron-chelating medication was ineffective — to include adults and children, ages 3 and older, with SCD or other anemias.
- Health Canada has expanded its approval of Ferriprox (deferiprone) to patients who have blood transfusion-induced iron overload due to sickle cell disease (SCD) or other anemias.
Sources:
https://sicklecellanemianews.com/2021/10/19/health-canada-ferriprox-treat-iron-overload-sickle-cell-disease/
https://sicklecellanemianews.com/2021/09/16/ferriprox-approved-brazil-iron-overload-scd-other-anemias/